Back to top
more

RxSight (RXST)

(Delayed Data from NSDQ)

$7.19 USD

7.19
1,667,105

-0.60 (-7.70%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $7.20 +0.01 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

Zacks Equity Research

Is a Beat Likely for Intuitive Surgical (ISRG) in Q4 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

Zacks Equity Research

CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Zacks Equity Research

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

Zacks Equity Research

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.

Zacks Equity Research

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

Zacks Equity Research

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

by Zacks Equity Research

Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

RxSight, Inc. (RXST) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Zacks Equity Research

RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Zacks Equity Research

RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Zacks Equity Research

Has Alcon (ALC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.

Zacks Equity Research

The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight

by Zacks Equity Research

Abcam, Integer Holdings and RxSight are part of the Zacks top Analyst Blog.

Indrajit Bandyopadhyay headshot

3 Medical Device Stocks With Potential to Fight Deflation Risk

by Indrajit Bandyopadhyay

Here we discuss three medical devices stocks, ABCM, ITGR and RXST, which have robust growth outlook in the long term. Betting on these stocks will help investors offset any potential deflationary risk.

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 14.89% and 8.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?

by Zacks Equity Research

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy Now for Superlative Returns

by Tirthankar Chakraborty

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

Zacks Equity Research

How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%

by Zacks Equity Research

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.